
|
The Connection between Cancer & the Immune System
Cancer
Research Institute 2003In 1909, a scientist by the name of Paul Ehrlich
proposed that the incidence of cancer would be much
greater were it not for the vigilance of our immune
defense system in identifying and eliminating nascent
tumor cells. This suggestion gave birth to the generally
accepted concept that the immune system plays a vital
role in the identification and elimination of
transformed cells. About 50 years later, two scientists,
Lewis Thomas and Frank MacFarlane Burnet, took Paul
Ehrlich’s original idea a step further and proposed that
a special type of immune cell called a T cell was the
pivotal sentinel in the immune system’s response against
cancer. This elaboration led to the coinage of the term
“immune surveillance or immunosurveillance” to describe
the concept whereby the immune system is on perpetual
alert against transformed cells.
As dictated by the scientific method, theories must in
the course of time either withstand rigorous
experimental testing, crumble and be discarded or be
improved upon. This basic requirement brought the theory
of immunosurveillance under severe attack and great
controversy when scientists like Osías Stutman showed in
the 1970s that mice supposedly lacking an intact immune
system (so-called nude mice) did not become more
susceptible to tumor growth as predicted by the theory.
Thus, the theory of immunosurveillance remained
controversial until an important scientific article
entitled “IFN-gamma and lymphocytes prevent primary
tumor development and shape tumor immunogenicity” was
published in the journal Nature on April 26, 2001. This
breakthrough article was authored by Robert D.
Schreiber, Ph.D., and his colleagues at Washington
University School of Medicine, St. Louis, MO, in
collaboration with Lloyd J. Old, M.D., of the Ludwig
Institute for Cancer Research and Memorial
Sloan-Kettering Cancer Center, New York, NY. The
experimental evidence presented in their paper
unambiguously showed that the immune system can and
often does prevent tumors from developing, and thus
plays a strong protective role against cancer. These
researchers also uncovered important new insights
regarding the immune system and tumor development that
they dubbed “immunoediting.”
Utilizing genetically engineered mice that lacked a
functional immune system, the authors showed that
lymphocytes and the immune stimulator, IFN-gamma,
cooperate to inhibit the development of both spontaneous
and carcinogen-induced tumors. Unfortunately, this
natural body defense is imperfect, and some tumor cells
escape identification and go on to cause cancer. These
renegade tumors are less immunogenic, having undergone a
process of immunoselection triggered by the actions of
the immune system. Conceptually, in much the same way as
bacteria can become resistant to antibiotic treatment
and lead to more potent and harmful strains, so too can
the body’s own tumor defense system lead to tumors that
escape elimination.
Importantly, these researchers went on to
demonstrate that there are ways to overcome the
“camouflage” of such renegade tumors by
increasing their antigen expression and making
them visible to the immune system. This suggests
that even tumors that have escaped recognition
can be turned into targets for an immune
response. Further experimentation is underway to
test how these results can be used to develop
cancer immunotherapies. The Cancer Research
Institute (CRI) sponsored this research with a
grant to Dr. Schreiber’s lab and provided
further funding through its pre- and
post-doctoral training programs to two graduate
students, one of whom was the first author of
the paper, and a postdoctoral fellow.
Despite the tremendous scientific progress (such
as that described above) that has been made over
the years, a complete and precise understanding
of the immune system’s response to cancer
remains elusive. The continued exploration of
these questions is the province of cancer
immunology; the scientific discipline to which
CRI is dedicated to supporting and nourishing.
FAIR USE NOTICE This article contains copyrighted material, the use of
which has not always been specifically authorized by the
copyright owner. I am making such material available in
my efforts to provide background knowledge on areas
related to canine cancer. I believe this constitutes a
'fair use' of any such copyrighted material as provided
for in section 107 of the US Copyright Law. In
accordance with
Title 17 U.S.C. Section 107,
the material in this article is distributed without
profit for educational purposes.
|
|

|